Hood River Capital Management LLC decreased its position in NuVasive, Inc. (NASDAQ:NUVA) by 52.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 281,495 shares of the medical device company’s stock after selling 309,455 shares during the period. NuVasive comprises 1.5% of Hood River Capital Management LLC’s portfolio, making the stock its 26th largest holding. Hood River Capital Management LLC owned 0.55% of NuVasive worth $21,653,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Westside Investment Management Inc. purchased a new stake in shares of NuVasive in the first quarter valued at about $109,000. FNY Partners Fund LP acquired a new stake in shares of NuVasive in the first quarter valued at about $112,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of NuVasive by 9.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,901 shares of the medical device company’s stock valued at $146,000 after purchasing an additional 158 shares during the period. Howard Hughes Medical Institute lifted its stake in shares of NuVasive by 82.8% in the second quarter. Howard Hughes Medical Institute now owns 2,066 shares of the medical device company’s stock valued at $159,000 after purchasing an additional 936 shares during the period. Finally, US Bancorp DE lifted its stake in shares of NuVasive by 1.7% in the first quarter. US Bancorp DE now owns 2,401 shares of the medical device company’s stock valued at $180,000 after purchasing an additional 41 shares during the period.
Shares of NuVasive, Inc. (NUVA) traded down 0.66% during midday trading on Friday, hitting $54.25. 720,806 shares of the stock were exchanged. NuVasive, Inc. has a one year low of $52.85 and a one year high of $81.68. The stock has a market cap of $2.76 billion, a P/E ratio of 85.43 and a beta of 1.08. The stock’s 50-day moving average price is $62.55 and its 200 day moving average price is $71.98.
NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The company had revenue of $260.60 million during the quarter, compared to analyst estimates of $261.95 million. During the same period in the prior year, the firm earned $0.40 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. On average, analysts anticipate that NuVasive, Inc. will post $2.00 earnings per share for the current year.
In related news, CEO Gregory T. Lucier purchased 5,000 shares of NuVasive stock in a transaction dated Thursday, August 17th. The stock was acquired at an average cost of $66.22 per share, with a total value of $331,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Peter Michael Leddy purchased 7,850 shares of NuVasive stock in a transaction dated Tuesday, August 1st. The stock was bought at an average cost of $63.88 per share, with a total value of $501,458.00. The disclosure for this purchase can be found here. Insiders have acquired 14,850 shares of company stock valued at $955,598 over the last ninety days. Insiders own 1.20% of the company’s stock.
Several analysts recently commented on NUVA shares. Royal Bank Of Canada raised their price objective on shares of NuVasive from $76.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, June 6th. Piper Jaffray Companies raised their price objective on shares of NuVasive from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Monday, June 12th. Zacks Investment Research cut shares of NuVasive from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. Cowen and Company reiterated an “outperform” rating and issued a $90.00 price objective (up previously from $85.00) on shares of NuVasive in a research note on Wednesday, June 28th. Finally, BidaskClub cut shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Wednesday, June 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $79.92.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.